Sang K. Sohn
Distinguished in Leukemia

Sang K. Sohn

Daegu, KR 
Distinguished in Leukemia
Daegu, KR 
OverviewLocationsClinical Research

Overview

Sang Sohn practices in Daegu, Republic of Korea. Mr. Sohn is rated as a Distinguished expert by MediFind in the treatment of Leukemia. His top areas of expertise are Leukemia, Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Bone Marrow Transplant.

His clinical research consists of co-authoring 115 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 58 articles and participated in 1 clinical trial in the study of Leukemia.

Gender
Male

Locations

Daegu, Republic of Korea
Other Locations
Seoul, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia
Enrollment Status: Unknown
Publish Date: July 24, 2018
Intervention Type: Drug
Study Drugs: Rituximab, Modified VPDL
Study Phase: Phase 2
View 1 Less Clinical Trial

115 Total Publications

Survival Benefits of Early Treatment With Blinatumomab in Adult Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Survival Benefits of Early Treatment With Blinatumomab in Adult Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Sohn's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile